For example, ACVR2A mutations are most frequent in hypermutated CRC and therefore, targeting up-regulated TRIB2 may potentially be suitable in such tumors, while BMP4 may be a better suited biomarker for CRC patients with SOX9 mutations and mesenchymal subtypes. This evidence concerns the gene SOX9 and colorectal carcinoma.